Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
about
Temporal information processing in short- and long-term memory of patients with schizophreniaA randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophreniaLongitudinal studies of cognition in first episode psychosis: a systematic review of the literatureF15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.Postural neurocognitive and neuronal activated cerebral blood flow deficits in young chronic fatigue syndrome patients with postural tachycardia syndromeAntipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanismsBrexpiprazole: so far so goodCan antipsychotics improve social cognition in patients with schizophrenia?A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia.Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophreniaContributions of early cortical processing and reading ability to functional status in individuals at clinical high risk for psychosisVerbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) study: the moderating role of smoking status and antipsychotic medicationsA randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophreniaCharacterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophreniaCriterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophreniaA psychometric investigation of "macroscopic" speech measures for clinical and psychological science.Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.The neural basis of theory of mind and its relationship to social functioning and social anhedonia in individuals with schizophrenia.Interaction of genotype and environment: effect of strain and housing conditions on cognitive behavior in rodent models of schizophrenia.Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.Models of neurodevelopmental abnormalities in schizophrenia.Lack of relationship between acoustic startle and cognitive variables in schizophrenia and control subjectsThe 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders.Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia?The relationship between preattentive sensory processing deficits and age in schizophrenia patientsUsing the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps?Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia.Irradiation in adulthood as a new model of schizophrenia.F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.Optimizing vs. matching: response strategy in a probabilistic learning task is associated with negative symptoms of schizophrenia.Adapting social neuroscience measures for schizophrenia clinical trials, Part 2: trolling the depths of psychometric propertiesNear-infrared spectroscopy in schizophrenia: a possible biomarker for predicting clinical outcome and treatment response.Social Cognition Psychometric Evaluation: Results of the Initial Psychometric StudyExecutive attention impairment in first-episode schizophrenia.Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics.The puzzle of schizophrenia: tracking the core role of cognitive deficits.Apathy is associated with executive functioning in first episode psychosis.Differentiating the cognitive profile of schizophrenia from that of Alzheimer disease and depression in late life.
P2860
Q21134998-3D4EE5AA-A16E-4C48-A1E3-9EAD1761105DQ21203917-1A425B6D-3E73-4EFB-9BBF-52E64BE09198Q22241267-1519287B-2CEC-4FFD-B3ED-D288C98CF0DBQ24564963-1F8760B1-8426-4908-BC4A-76EE9CDBE6D4Q24610647-0FAC464C-3231-48D5-946C-F6DFBC63B43FQ26745506-28CC099E-4864-49CB-8A26-AB015B4512BFQ26766401-7102B549-E7CE-4889-8C5D-AB5908636970Q26822977-F4E7F40E-E229-46E4-B2D7-BFC021F5F5D8Q27001119-49E09D39-4377-4699-A6C6-3145E71409E6Q27014120-B6EDBD63-D933-4E9C-AC7D-883591CB30AEQ27303931-613E1524-4EDE-4B57-8387-14087D2779B5Q27303941-BC687062-2332-4677-9994-DE56FFD8FC3FQ28263502-721147C0-DF10-43CE-A3BF-5AF55DFB8488Q28727584-64CED6AF-FA11-428E-ACB2-9BBA05575964Q28744227-BEBD1FDD-8907-407C-A80D-60560A16FBEEQ30354975-D25A1BCF-8D73-4EBD-98D9-C944C713379CQ30396291-BEC2E7C6-E560-4164-A454-AE48F8987749Q30445421-B7F2A794-878D-4D6F-ACED-784FAFFE2F9BQ30451282-C8155395-B9DD-4ECD-A996-E6B32161C9B6Q30455599-80153A3E-1460-46A7-BABF-78B6FFB86F64Q30457462-65DC0FF9-ED42-438A-B253-DD2521F81373Q30467332-41969E15-7366-40A9-B0B7-BF8B29F4EEACQ30468033-ADF49415-A611-46FB-A7D3-A8D175D5EF1BQ30469285-6B0C2121-64D2-44F8-8601-6BFEB3F97BFEQ30473418-3FD149A6-9448-4C1C-BE14-D0E4403CD480Q30478849-5F56F2B6-B98E-4B6F-923F-F189C6D29FBCQ30489404-15976218-D51E-4B80-8895-E1FA4DC6D63FQ30490231-30E6156F-0BF3-44C6-8FFC-80D2544C2302Q30491339-BAD48DFD-401A-42E9-9AB2-CAC1481E7854Q30494355-E7D00919-EF35-4AF3-B1E7-8CB43872F694Q30494674-3469919A-E24F-4FA4-9F95-9BB5E47E89D7Q30498397-B47F0600-0765-44DA-A8D4-043F282324FBQ30550244-428DA0FF-259A-4C5B-952D-7ABA31D15B65Q30705133-08368171-E2BD-403B-9B76-7A01FE77EE8BQ30711959-7F15CDCC-7048-49DB-AF23-4473FB6D29E4Q31098898-6AC64726-C8BE-4BFA-AF0E-20592EBA5A5CQ31108616-7D48F367-6E34-4D45-B73D-B866572E9D70Q33353490-91998769-73D9-470F-8A10-6D886956EEA7Q33398673-87A0C0A6-9D6D-4315-BDCF-F22E9A44D9CBQ33559923-4ACCA09F-1E6A-4ABA-B684-2953733B2331
P2860
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Approaching a consensus cognit ...... ive domains and test criteria.
@ast
Approaching a consensus cognit ...... ive domains and test criteria.
@en
type
label
Approaching a consensus cognit ...... ive domains and test criteria.
@ast
Approaching a consensus cognit ...... ive domains and test criteria.
@en
prefLabel
Approaching a consensus cognit ...... ive domains and test criteria.
@ast
Approaching a consensus cognit ...... ive domains and test criteria.
@en
P2093
P50
P1476
Approaching a consensus cognit ...... ive domains and test criteria.
@en
P2093
Ellen Stover
Fred Frese
James M Gold
Jonathan Cohen
Richard S E Keefe
Robert S Kern
Stephen R Marder
Steven Zalcman
Susan Essock
Terry E Goldberg
P304
P356
10.1016/J.BIOPSYCH.2004.06.023
P407
P50
P577
2004-09-01T00:00:00Z